P&T COMMITTEE MEETING

Agenda April 7, 2020
1:00 p.m. - 5:00 p.m.

Virtual Meeting via Zoom
https://magellanhealth.zoom.us/webinar/register/WN_K3YPhtNRR6t3-Jpm376Bw

□ Committee Member Introductions

Unfinished Business and General Orders
• Approval of minutes from January 7, 2020 P&T meeting
• Update on Antimigraine Agents - Calcitonin Gene-Related Peptide (CGRP) Inhibitors
• Update on Diabetes Management - Insulins
• Update on Glucagon, Self-Administered
• Update on Multiple Sclerosis Agents
• Update on Immune Globulins
• Update on Anti-Parkinson’s Agents
  o Dopa Decarboxylase Inhibitors & Combinations
  o MAO-Bs
  o Dopamine Agonists
  o Other
• Update on Atypical Antipsychotics
• Update on Lithium Agents
• Update on Ophthalmic Allergy Agents
• Update on Ophthalmic Anti-Inflammatories
• Update on Ophthalmic Glaucoma Agents
• Update on Intranasal Rhinitis Agents
• Update on Lipotropics
• Update on Statins & Statin Combinations
• Update on Hemorrhoidal and Related Anorectal Agents
• Mass review drug classes:
  o Bile Salts
  o Growth Hormones
  o Leukotriene Modifiers
  o Neurocognitive Disorder Agents
  o Sedative Hypnotics
    ▪ Non-Benzodiazepine
    ▪ Benzodiazepine
  o Topical Steroids
    ▪ Low Potency
    ▪ Medium Potency
    ▪ High Potency
    ▪ Very High Potency
New Business
• Updates from the Prior Authorization Call Center

Drug Classes Up for Review:
• Review of Non-Opioid Analgesics
• Review of Opioids - Long-Acting
• Review of Opioids - Short-Acting
• Review of Tetracyclines
• Review of Angiotensin Modulators and Angiotensin Modulator Combinations
  o ACE Inhibitors, ACE Inhibitor Combinations
  o ARBs, ARB Combinations
  o Renin Inhibitors & Combinations
• Review of Acne Agents
  o Topicals
  o Oral Isotretinoins
• Review of Androgenic Agents
  o Topicals
  o Injectables
  o Orals
• Review of Respiratory Inhalants
  o Inhaled Anticholinergics & Anticholinergic Combinations
  o Inhaled Beta₂ Agonists (short-acting)
  o Inhaled Beta₂ Agonists (long-acting)
  o Inhaled Corticosteroids and Combinations
• Mass review drug classes:
  o Review of Skeletal Muscle Relaxants
  o Review of Rosacea Agents, Topical
  o Review of Antihistamines, Newer Generation & Combinations
  o Review of Topical Immunomodulators
  o Review of Phosphate Binders
  o Review of Benign Prostatic Hypertrophy (BPH) Agents

Each Review will contain:
• Oral presentation by manufacturers, providers, and public
• Overview for each Drug Class, including market share overview
• Committee Discussion and Recommendations for each Class
Mass review drug classes will only include:
• Overview for each Drug Class, including market share overview

Presentations:
• Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.
• Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com and carbon copy: Brittany Schock, PDL Pharmacist, brittany.schock@state.co.us. Once approved, public comments will be distributed to P&T Committee Members. Due to Virtual venue change, public comments were due by March 31st, 2020 by 5pm MST.

Upcoming Meeting Date: Tuesday, July 14, 2020; 1:00 p.m. - 5:00 p.m.